Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of XL147 in combination
with erlotinib (Tarceva®) in subjects with solid tumors. XL147 is a new chemical entity that
inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce
apoptosis (programmed cell death) in tumor cells. Erlotinib is an orally administered
inhibitor of EGFR (also known as HER1) tyrosine kinase. It was approved by the FDA as a
single agent for the treatment of patients with locally advanced or metastatic non-small-cell
lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen and in
combination with gemcitabine for first line treatment of patients with locally advanced,
unresectable or metastatic pancreatic cancer.